Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VM202 (Engensis) gene therapy in ischemic heart disease after CABG
NCT01422772Phase 2Completed
- Sponsor
- Helixmith
- Start
- Jan 2007
- Primary completion
- Feb 2010
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
Phase 2, open-label trial of Engensis in ischemic heart disease (IHD) (3 cohorts), sponsored by Helixmith. Primary endpoints: Adverse Events at 24 weeks, Adverse Events by Severity at 24 weeks and 3 more. Started Jan 2007; status: completed.
02
Drugs
Engensis
03
Conditions
ischemic heart disease (IHD)
Beyond the preview
Go deeper on NCT01422772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01422772.